HLNCF Quote, Financials, Valuation and Earnings

Autolus Therapeutics PLC has a net margin of 8.37% compared to Haleon PLC's net margin of -781.13%. Haleon PLC's return on equity of 8.91% beat Autolus Therapeutics PLC's return on equity of -49.92%.

Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 303.92%. Given that Autolus Therapeutics PLC has higher upside potential than Haleon PLC, analysts believe Autolus Therapeutics PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.

Haleon PLC has a quarterly dividend of $0.06 per share corresponding to a yield of 1.8%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are larger than Autolus Therapeutics PLC quarterly revenues of $9M. Haleon PLC's net income of $295.8M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Haleon PLC's price-to-earnings ratio is 26.00x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2041.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Haleon PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

Haleon PLC has a quarterly dividend of $0.06 per share corresponding to a yield of 1.8%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 26.00x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus 0.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat NuCana PLC's return on equity of --.

Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 207071.32%. Given that NuCana PLC has higher upside potential than Haleon PLC, analysts believe NuCana PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.

Haleon PLC has a quarterly dividend of $0.06 per share corresponding to a yield of 1.8%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are larger than NuCana PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than NuCana PLC's net income of -$3.1M. Notably, Haleon PLC's price-to-earnings ratio is 26.00x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of 8.37% compared to Haleon PLC's net margin of -21.4%. Haleon PLC's return on equity of 8.91% beat Verona Pharma PLC's return on equity of -85.84%.

Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Verona Pharma PLC has an analysts' consensus of $106.22 which suggests that it could grow by 1.42%. Given that Verona Pharma PLC has higher upside potential than Haleon PLC, analysts believe Verona Pharma PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.240, suggesting its less volatile than the S&P 500 by 76.016%.

Haleon PLC has a quarterly dividend of $0.06 per share corresponding to a yield of 1.8%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are larger than Verona Pharma PLC quarterly revenues of $76.3M. Haleon PLC's net income of $295.8M is higher than Verona Pharma PLC's net income of -$16.3M. Notably, Haleon PLC's price-to-earnings ratio is 26.00x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.